Licensing
← Отчётные звонки
01
02
03
04 05 06
Тон
Капзатраты
A1 A2 A3
CTVA
FY2025 Q4
Улучшается
Отчётный звонок Corteva, Inc.
Вывод Buzzberg
Bayer resolution accelerates royalty neutrality to 2026
Corteva's Q4 2025 call highlighted a landmark settlement with Bayer that accelerates its licensing strategy, particularly in corn and cotton. Management reiterated 2026 EBITDA guidance of $4.1 billion, reflecting a 7% growth, driven by licensing, new products, and productivity gains. The call also addressed challenges in the crop protection market, especially pricing pressure in Brazil, offset by strong demand for new products and biologics. 2025 was a record year with 22% EBITDA margins for the first time as a public company.
Вывод Buzzberg Bayer resolution accelerates royalty neutrality to 2026 Corteva's Q4 2025 call highlighted a landmark settlement with Bayer that accelerates its licensing strategy, particularly in corn and cotton. Management reiterated 2026 EBITDA guidance of $4.1 billion, reflecting a 7% growth, driven by licensing, new products, and productivity gains. The call also addressed challenges in the crop protection market, especially pricing pressure in Brazil, offset by strong demand for new products and biologics. 2025 was a record year with 22% EBITDA margins for the first time as a public company. Читать полный анализСвернуть анализ
Corteva's Q4 2025 call highlighted a landmark settlement with Bayer that accelerates its licensing strategy, particularly in corn and cotton. Management reiterated 2026 EBITDA guidance of $4.1 billion, reflecting a 7% growth, driven by licensing, new products, and productivity gains. The call also addressed challenges in the crop protection market, especially pricing pressure in Brazil, offset by strong demand for new products and biologics. 2025 was a record year with 22% EBITDA margins for the first time as a public company.
- Bayer settlement provides freedom to operate, accelerating corn licensing to 2027 and enabling US cotton licensing, with ~$1B EBITDA upside over 10 years.
- 2026 guidance: EBITDA midpoint $4.1B, EPS $3.45-$3.70, with expectations of 60% of sales and 85% of EBITDA in H1.
- Crop protection expects modest market growth in 2026 with volume growth in durables, but faces price pressure in Latin America and Asia Pacific.
Выручка$3.91BФакт
EPS$0.22Факт
Валовая маржа42.35%Факт
Операционная маржа6.19%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Licensing
Bayer agreement to generate ~$1B EBITDA upside over 10 years
Licensing
Corn licensing accelerated to 2027, five years earlier
Показать ещё 3 тезиса
Innovation
Third-gen above-ground trait platform accelerated by two years
Demand
Crop protection market expected to grow modestly in 2026
Innovation
Gene-edited fungal disease resistant corn near commercialization
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $3.91B | Факт |
| EPS | $0.22 | Факт |
| Валовая маржа | 42.35% | Факт |
| Операционная маржа | 6.19% | Факт |
| Свободный денежный поток | $4.153B | Факт |
| Капзатраты | $0.222B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Операционная маржа | FY2026 | 22% | 22% | Обозначен |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management expressed confidence in 2026 guidance, highlighted record performance, and emphasized accelerated opportunities from the Bayer resolution.
Инвестиции и мощности
Management did not provide specific capital expenditure guidance, but mentioned ongoing asset and sourcing optimization in crop protection and investments in innovation, R&D at just over 8% of sales, and separation-related IT system separation costs.
все упомянутые компании ниже: 1
Компаниис момента звонка
Партнёры
Партнёры
Chuck Magro
Bayer settlement accelerates Corteva's corn licensing to 2027 (5 years early) and introduces cotton licensing, with a $1B EBITDA upside over 10 years. — Opens new revenue streams for Corteva and potentially increases competitive pressure on Bayer's seed businesses.
Доказательства
“We recently reached a comprehensive resolution with Bayer related to our seed, Freedom to Operate.”
Внешние сигналы
Альфа цепочки поставок · 3с момента звонка
Bayer settlement accelerates Corteva's corn licensing to 2027 (5 years early) and introduces cotton licensing, with a $1B EBITDA upside over 10 years.
Доказательства
“This resolution also facilitates the introduction of our third gen above ground trade platform in North America corn, which will be available for branded sales and licensing by the end of the decade.”
The 2026 tariff impact is $80M, mostly on crop protection from China-sourced active ingredients entering the US.
Доказательства
“The estimate that we've got on the crop protection primarily is where the tariffs all are is encompassing everything we've got for the entire business... almost all of it is CP and almost all of it is China actives coming in to the United…”
Corteva expects to reach royalty neutrality in 2026, two years ahead of schedule, due to the Bayer settlement and licensing progress.
Доказательства
“As a result of this resolution and the progress we've been making across the broader outlicensing spectrum, we now expect to achieve royalty neutrality in 2026, which is two years ahead of our most recent expectations.”
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 1. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.